Donaldson Gears Up to Report Q3 Earnings: What's in the Offing?

Donaldson (DCI) is expected to report fiscal Q3 2025 earnings on June 3rd, with consensus estimates projecting revenues of $940.5 million and adjusted EPS of $0.95, representing year-over-year increases of 1.4% and 3.3%, respectively. Strength in the commercial aerospace and defense markets is expected to drive growth in the Industrial Solutions segment, while the acquisition of Medica S.p.A. should support overall results; however, rising SG&A expenses could pressure margins. Zacks' model predicts an earnings beat, citing a positive Earnings ESP of +3.74%.

Analysis

Donaldson Company (DCI) is poised to report its third-quarter fiscal 2025 earnings on June 3rd, with analysts forecasting revenues of $940.5 million, reflecting a 1.4% year-over-year increase, and adjusted earnings per share of 95 cents, a 3.3% rise from the corresponding quarter last year. The Industrial Solutions segment is anticipated to be a key growth driver, with projected revenues of $284 million, up 5.6% year-over-year, benefiting from strong momentum in commercial aerospace and increased demand in defense markets. The Life Sciences segment is also expected to show growth, with consensus revenue pegged at $75 million, a 1.4% year-over-year increase, driven by demand for disk drives and food & beverage products in Europe, the Middle East, Africa, and the Asia Pacific region. However, the Mobile Solutions segment is expected to see a slight revenue decline of 1.2% year-over-year to $578 million, primarily due to softness in agriculture markets and reduced global truck production, although this figure would mark a 5.5% improvement over the previous quarter, supported by aftermarket business strength. The August 2024 acquisition of a 49% stake in Medica S.p.A. is anticipated to positively influence results by facilitating entry into new medical device and water purification markets. A primary concern for the quarter is the potential for escalating selling, general, and administrative (SG&A) expenses, stemming from increased headcount and investments in acquired businesses, which could exert pressure on DCI's margins. While DCI missed earnings estimates by 2.4% in the last reported quarter, it has surpassed consensus in three of the past four quarters, with an average positive surprise of 3.8%. Zacks' proprietary model indicates a likely earnings beat for the upcoming announcement, citing a positive Earnings ESP of +3.74%, as the Most Accurate Estimate of 99 cents per share exceeds the Zacks Consensus Estimate of 95 cents, and the company holds a Zacks Rank #3 (Hold).

Key Decisions for Investors

• Investors should closely examine Donaldson's Q3 fiscal 2025 earnings report on June 3rd, paying particular attention to revenue and EPS figures relative to consensus, and scrutinize any updates to the full-year outlook.
• It is advisable to assess the specific performance within the Industrial Solutions and Life Sciences segments as key growth indicators, while also evaluating the impact of headwinds on the Mobile Solutions segment and the extent of margin pressure from rising SG&A expenses.
• Consider the initial financial contribution and strategic commentary regarding the integration of Medica S.p.A., particularly its role in diversifying into the medical device and water purification sectors.
• While the positive Earnings ESP and Zacks model suggest a potential earnings beat, this should be weighed against the company's recent earnings miss and the highlighted risk of margin compression due to increased operating costs.